Casirivimab – Imdevimab in Covid 19 – Early Indian experienceCasirivimab - Covid 19의 Imdevimab - 초기 인도 경험Article Published on 2022-07-012022-09-12 Journal: The Indian journal of tuberculosis [Category] 진단, [키워드] Casirivimab Imdevimab [DOI] 10.1016/j.ijtb.2021.09.014 PMC 바로가기 [Article Type] Article
Advances in the Omicron variant developmentOmicron 변종 개발의 발전Review Published on 2022-07-012022-09-11 Journal: Journal of internal medicine [Category] COVID19(2023년), SARS, 변종, 진단, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus addition advance Alpha Amino acid amino acids Antiviral antiviral agent Antiviral agents antiviral drugs approved Beta booster dose booster doses Casirivimab circulating coronavirus COVID-19 Delta disease dominant dose drug effective entry of SARS-CoV-2 Epidemiology epitope Epitopes Gamma greater greater transmissibility growth advantage Health Organization humoral Imdevimab Immune escape incidence Infection inhibit Mild mild illness molecular molnupiravir monoclonal monoclonal antibodies monoclonal antibody mutations offer omicron Omicron variant pandemic Paxlovid pharmacological agent pharmacological agents Remdesivir Research respiratory SARS-CoV-2 SARS-CoV-2 virus severe acute respiratory syndrome Coronavirus Spike protein Spread the spike protein therapeutic to define Transmissibility vaccination Vaccine Vaccines variant variants Viral viral replication VoC WHO World Health Organization [DOI] 10.1111/joim.13478 PMC 바로가기 [Article Type] Review
Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study질병 진행 위험이 높은 경증에서 중등도 COVID-19 환자를 대상으로 한 다양한 단일 클론 항체 요법의 임상 효능: 전향적 코호트 연구Observational Study Published on 2022-07-012022-09-11 Journal: European Journal of Clinical Microbiology & Infect [Category] COVID19(2023년), SARS, 변종, 임상, 진단, 치료기술, [키워드] (alpha 95% CI 95% confidence interval adjusted odds ratio analysed anti-SARS-CoV-2 antibody treatment B.1.1.7 bamlanivimab Bamlanivimab-etesevimab, casirivimab-imdevimab baseline Baseline serology Casirivimab circulating variants clinical Clinical outcome clinical outcomes combination regimen conducted COVID-19 COVID-19 outpatient COVID-19 outpatients COVID-19 progression disease Efficacy eight etesevimab Factor groups high risk high-risk population hospital hospitalisation hospitalised Imdevimab Italian Logistic regression mAb Medicine Mild Mild-to-moderate Mild-to-moderate COVID-19 outpatients Moderate COVID-19 monoclonal antibodies monoclonal antibody Monoclonal antibody treatments Monoclonal antibody treatments for COVID-19 multivariable no significant difference no significant differences non-hospitalised Outpatient Patient patient subgroup patients progression proportion prospective cohort study Prospective Study Randomised trial randomised trials receiving regimen SARS-CoV-2 SARS-CoV-2 early treatments. SARS-CoV-2 vaccination SARS-CoV-2 variant serology significant differences significantly higher significantly lower The B.1.1.7 treated vaccination variant [DOI] 10.1007/s10096-022-04464-x PMC 바로가기 [Article Type] Observational Study
Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 TherapyCOVID-19 치료에 사용되는 항체에 의한 중화로부터 보호할 수 있는 ACE2 독립적 진입 경로에 대한 증거Article Published on 2022-06-282022-09-11 Journal: mBio [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, 치료제, [키워드] ACE2 ACE2 binding analyzed antibody Antibody-mediated neutralization blockade Can cell entry cell line cellular receptor COVID-19 COVID-19 patient COVID-19 therapy E484K Evidence hepatoma host cells Huh-7 Imdevimab Infection Interaction lung cell mechanism Mutation NCI-H1299 neutralization Neutralizing antibodies neutralizing antibody position PROTECT Protein rescued SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variants spike Spike protein the SARS-CoV-2 therapy vaccination variants of concern Vero Cell Viral viral entry virus VoC [DOI] 10.1128/mbio.00364-22 PMC 바로가기 [Article Type] Article
Effect of Casirivimab/Imdevimab Treatment on Serum Type I Interferon Levels in SARS-CoV-2 InfectionSARS-CoV-2 감염에서 혈청 I형 인터페론 수치에 대한 Casirivimab/Imdevimab 치료의 효과Observational Study Published on 2022-06-272022-09-12 Journal: Viruses [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] addition administration Antibody-dependent enhancement Blood level Casirivimab Cohort Comparator group consecutive patient COVID-19 cytokine Dexamethasone early phase Effect enrolled evaluated Hospitalized Hypoxemia IFN-I IFN-α IFN-β Imdevimab immune response immunoassay Infection innate immune response interferon Level on type onset of symptoms Patient patients with SARS-CoV-2 prospective observational study recruited Remdesivir SARS-CoV-2 SARS-COV-2 infection significantly temperature therapeutic effect Treatment Type type I interferon were assessed [DOI] 10.3390/v14071399 PMC 바로가기 [Article Type] Observational Study
COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection혈액 투석실에서 예방 접종을 받은 환자의 COVID-19 발생: 감염으로부터 보호하는 지표로서의 항체 역가Article Published on 2022-06-232022-09-11 Journal: Nephrology, dialysis, transplantation : official p [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Alpha Alpha variant anti-S anti-S IgG Anti-spike Antibody titre BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccination BNT162b2 vaccine Casirivimab cause Clinical data Combination confidence interval coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 infection COVID-19 outbreak dialysis dialysis room Haemodialysis humoral Humoral response identify IgG Imdevimab immune correlate immune correlates Immunoglobulin Immunoglobulin G Immunosuppression increased risk Infection interquartile range IQR marker monoclonal antibodies monoclonal antibody mRNA vaccination multivariable analysis neutralization Odds ratio outbreak Patient patients prevented recorded reduced respiratory SARS-CoV-2 SARS-COV-2 infection serological response severe acute respiratory syndrome Coronavirus severe coronavirus disease severe COVID-19 severe disease the patient titre treated uninfected vaccination Vaccines variant were infected with COVID-19 [DOI] 10.1093/ndt/gfac016 PMC 바로가기 [Article Type] Article
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2SARS-CoV-2 오미크론 하위 계통 BA.1 및 BA.2에 대한 허가된 단일 클론 항체 및 항바이러스제의 효능Article Published on 2022-06-232022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, 진단, 치료제, [키워드] active against agent Antiviral antiviral drugs assays B.1 bamlanivimab Casirivimab cell-based assay Concentration Cytopathic effect defined drug activity etesevimab Evolution of SARS-CoV-2 Ex vivo Imdevimab individual Lineage lineages Live virus mAb mAbs microneutralization Microneutralization assay molnupiravir monoclonal antibodies monoclonal antibody neutralized Neutralizing activity Nirmatrelvir omicron omicron sublineages remained Remdesivir SARS-CoV-2 SARS-CoV-2 variant sera serum dilution SOT Sotrovimab the SARS-CoV-2 treated wild-type [DOI] 10.3390/v14071374 PMC 바로가기 [Article Type] Article
An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo조작된 ACE2 미끼는 SARS-CoV-2 Omicron 변이체를 중화하고 생체 내 감염으로부터 보호합니다.Article Published on 2022-06-222022-09-11 Journal: Science Translational Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료제, [키워드] ACE2 Alpha alpha and delta variants Analysis analyzed angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 antibodies B.1.1.529 BNT162b2 breakthrough infections Casirivimab chimeric Complete conserved conserved region contributed convalescent serum deep delta variant Delta variants demonstrated dose drugs effective enzyme escape escaped evade exhibited Frequency hamster hamsters human ACE2 Imdevimab immunized in vivo individual Infection multiple mutation multiple mutations Mutation N-terminal domain neutralization neutralization titer neutralize neutralized of BNT162b2 omicron parental prevented pseudo-virus raising Receptor binding domain sarbecovirus SARS-CoV-2 variant SARS-CoV-2 variants sensitivity serum serum sample serum samples Sotrovimab Spike protein Spike proteins target the SARS-CoV-2 the spike protein theory therapeutic therapeutic antibodies therapeutic effect transgenic mice vaccination Vaccines variant variants Viral viral mutation virus virus-neutralizing Wuhan strain [DOI] 10.1126/scitranslmed.abn7737 PMC 바로가기 [Article Type] Article
Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infectionSARS-CoV-2 델타 변이형 감염 고위험 환자의 질병 중증도 결과에 대한 카시리비맙-임데비맙 치료의 의심스러운 임상 이점Article Published on 2022-06-012022-09-11 Journal: European journal of internal medicine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Abstract BNT162b2 BNT162b2 vaccine Casirivimab Casirivimab/Imdevimab therapy clinical benefit disease severity high-risk patient High-risk patients Imdevimab Infection outcome SARS-CoV-2 delta SARS-CoV-2 Delta variant severe outcome Treatment variant [DOI] 10.1016/j.ejim.2022.03.001 PMC 바로가기 [Article Type] Article
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fallArticle Published on 2022-06-012023-07-08 Journal: Expert opinion on drug discovery [Category] COVID19(2023년), [키워드] Casirivimab Imdevimab REGEN-COV REGN-CoV-2 Ronapreve [DOI] 10.1080/17460441.2022.2058486